Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients

Feng, Zizhen; Graff, Julie N.

doi:10.1007/s40266-020-00809-3

Cited by 9 publications

(9 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an unmet need for assessing the potential benefits of lower-dose anticancer treatments, particularly in frail or comorbid patients 29 who may experience substantial toxicity when given registered doses. 30 31 The development of anticancer drugs continues to rely on historical paradigms for cytotoxic chemotherapy (maximum tolerated dose, MTD) which is rarely reconsidered after approval or labelling.…”

Section: Discussionmentioning

confidence: 99%

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review

Bromley,

Varughese,

Gilbert

et al. 2024

bmjonc

View full text Add to dashboard Cite

ObjectiveTo review the efficacy and safety of low-dose versus standard-dose enzalutamide, apalutamide or darolutamide treatment for metastatic prostate cancer.Methods and analysisKeyword searches in MEDLINE and EMBASE up to 1 June 2023, with forward and backward citation searches of potentially relevant studies. Studies were included if primary outcome data were reported for patients with metastatic prostate cancer who had received reduced doses of enzalutamide, apalutamide or darolutamide. Searches were limited to original full-text and English-language studies. Key outcomes included overall survival (OS), progression-free survival (PFS), prostate-specific antigen response and treatment-related adverse events. The review was performed in accordance with Cochrane Rapid Reviews Methods Group guidelines.ResultsTen studies were identified that met the eligibility criteria: five phase I studies, two post-hoc analyses of phase III trials and three retrospective analyses. No consistent association between OS, PFS and drug dose was identified. Fewer severe treatment-related adverse events were observed at lower drug doses.ConclusionThis review provides evidence that enzalutamide, apalutamide or darolutamide could be given at a lower than the standard recommended dose without loss of antitumour activity. A prospective near-equivalence randomised trial should be undertaken to compare registered and lower doses of these agents.PROSPERO registration numberCRD42023440371.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review

Bromley,

Varughese,

Gilbert

et al. 2024

bmjonc

View full text Add to dashboard Cite

show abstract

“…The reasons for drug switches were not known in our study. Given the respective safety profiles of ABI and ENZ, including cardiac disorders or cognitive disorders 14,22,23 , the occurrence of adverse drug reactions among patients with comorbidities cannot be excluded and could be a factor for definitive discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide

Scailteux

Vincendeau

Gravis

et al. 2023

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…When analysed holistically, the three drugs share significant efficacy by measure of MFS; all three increased MFS by approximately 2 years MFS compared with placebo. 24,25 At a more granular level, a recent network meta-analysis showed that enzalutamide had a slight advantage in MFS and time to PSA progression over darolutamide, but no significant differences were observed between enzalutamide and apalutamide. 26 This sort of analysis is insufficient to inform treatment selection.…”

Section: Considerations In Therapy Selectionmentioning

confidence: 99%

New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer

Sinit¹,

Graff²

2021

Oncology &Amp; Haematology

View full text Add to dashboard Cite

Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients

Cited by 9 publications

References 78 publications

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review

Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide

New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer

Contact Info

Product

Resources

About